• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Commits to Veeva Vault CRM

    7/21/25 10:00:00 AM ET
    $MRK
    $VEEV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $MRK alert in real time by email

    Deep application provides foundation for commercial execution

    PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.

    Veeva Systems (PRNewsfoto/Veeva Systems)

    The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities.

    "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Dave Williams, executive vice president and chief information and digital officer at Merck. "We share a deep commitment to customer success, and Vault CRM will provide Merck the technology foundation to drive commercial execution."

    "Merck has consistently been at the forefront of leading-edge science that improves the lives of millions around the world," said Veeva CEO Peter Gassner. "We are honored to be a strategic partner to Merck and it is great to see our partnership extend to Vault CRM."

    Vault CRM is part of the Vault CRM Suite of deep applications that drive more effective commercial execution across personal and digital channels. With advanced global capabilities, Vault CRM Suite addresses the industry's unique regional and country-specific business and compliance requirements. 

    About Veeva Systems

    Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

    Contact:

     



    Maria Scurry

    Veeva Systems

    [email protected]

    Meera Lakhani-Patel

    Veeva Europe

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/merck-commits-to-veeva-vault-crm-302509227.html

    SOURCE Veeva Systems

    Get the next $MRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK
    $VEEV

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    1/13/2026$215.00Sell
    Goldman
    Veeva Systems Inc.
    $VEEV
    1/8/2026Hold → Buy
    Truist
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Veeva Systems Inc.
    $VEEV
    12/12/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Merck & Company Inc.
    $MRK
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    Veeva Systems Inc.
    $VEEV
    11/13/2025$300.00Market Perform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    11/13/2025$105.00Sector Outperform
    Scotiabank
    More analyst ratings

    $MRK
    $VEEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Veeva Systems with a new price target

    Goldman resumed coverage of Veeva Systems with a rating of Sell and set a new price target of $215.00

    1/13/26 9:18:31 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Systems upgraded by Truist

    Truist upgraded Veeva Systems from Hold to Buy

    1/8/26 9:27:19 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Merck upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Merck from Peer Perform to Outperform and set a new price target of $135.00

    1/8/26 8:11:51 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Marketing Officer Guindo Chirfi sold $1,184,101 worth of shares (10,000 units at $118.41), decreasing direct ownership by 12% to 70,615 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/9/26 4:04:59 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Zachary Jennifer exercised 121,573 shares at a strike of $119.15 and sold $14,485,690 worth of shares (121,573 units at $119.15) (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/9/26 4:01:25 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Info&Digital Officer Williams David Michael exercised 5,000 shares at a strike of $77.62 and sold $609,525 worth of shares (5,000 units at $121.91), decreasing direct ownership by 0.00% to 30,838 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/6/26 4:20:14 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants

    Approval is based on the CLEVER and SMART Clinical Trial Results KIRKLAND, QC, Feb. 5, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants born during or entering their first RSV season. ENFLONSIA® is a monoclonal antibody (mAb) that can help provide protection for up to five months—typical of an RSV season. The Health Canada approval marks an important

    2/5/26 7:05:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    13 of the Top 20 Biopharmas Standardize Globally on Veeva Link Key People

    Emerging biotechs and top biopharmas trust Link to power customer engagement and provide structured datasets to fuel AI initiatives PLEASANTON, Calif., Feb. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that 13 of the top 20 biopharmas have standardized on Veeva Link Key People to enhance customer engagement and provide data for AI globally. Biopharmas of all sizes use Link Key People, with 38 new customers added and three of the top 20 biopharmas making it their global standard within the last year. "Access to Veeva Link Key People further strengthens data

    2/4/26 7:03:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    SEC Filings

    View All

    SEC Form 144 filed by Merck & Company Inc.

    144 - Merck & Co., Inc. (0000310158) (Subject)

    2/4/26 4:38:27 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    2/3/26 6:38:40 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veeva Systems Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - VEEVA SYSTEMS INC (0001393052) (Filer)

    1/5/26 4:04:59 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $MRK
    $VEEV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/16/24 4:29:43 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/14/24 3:12:28 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/14/24 10:03:02 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $MRK
    $VEEV
    Financials

    Live finance-specific insights

    View All

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Second-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    1/27/26 3:07:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 3. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and C

    1/7/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components